Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds - Seite 3
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: (1) the financing strengthening the Company’s
financial flexibility, allowing it to accelerate the growth of its business and evaluate and pursue compelling business development opportunities that have the potential to expand its existing
product portfolio; (2) planned closing of the Private Placement during the first week of September; and (3) Ms. Asher Topilsky's statement regarding the appointment of the two new directors and
leveraging the successful track records of both, which is important as the Company continues to develop its business and pipeline while evaluating potential new opportunities. Forward-looking
statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results
and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, success in expanding
Kamada’s product portfolio through business development initiatives, Kamada’s ability to consummate any business development opportunities, success in integrating any business development
opportunities within Kamada’s existing business, availability of sufficient raw materials required to maintain manufacturing plans, continued utilization of Kamada’s Israeli manufacturing site,
continuation of inbound and outbound international delivery routes, continued demand for the IgG product portfolio, FDA and international health authorities’ approval process, financial conditions
of the Company’s customers, suppliers and services providers, Kamada’s ability to integrate the new product portfolio into its current product portfolio, Kamada’s ability to grow the revenues of
its new product portfolio, and leverage and expand its international distribution network, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes,
regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada’s filings
with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on
file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no
obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.